These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26986934)

  • 21. SnapShot: glioblastoma multiforme.
    Kotliarova S; Fine HA
    Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
    [No Abstract]   [Full Text] [Related]  

  • 22. The challenges associated with molecular targeted therapies for glioblastoma.
    Jue TR; McDonald KL
    J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
    Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
    Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
    Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of Rb cooperates with Ras to drive oncogenic growth in mammalian cells.
    Collins MJ; Napoli I; Ribeiro S; Roberts S; Lloyd AC
    Curr Biol; 2012 Oct; 22(19):1765-73. PubMed ID: 22885065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glioblastoma precision therapy: From the bench to the clinic.
    Zhou Y; Wu W; Bi H; Yang D; Zhang C
    Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3Kinase signaling in glioblastoma.
    Lino MM; Merlo A
    J Neurooncol; 2011 Jul; 103(3):417-27. PubMed ID: 21063898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.
    Zhou A
    Curr Pharm Des; 2017 Nov; 23(29):4290-4302. PubMed ID: 28699529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using genomics to guide treatment for glioblastoma.
    Young JS; Prados MD; Butowski N
    Pharmacogenomics; 2018 Oct; 19(15):1217-1229. PubMed ID: 30203716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
    Bastien JI; McNeill KA; Fine HA
    Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme.
    da Silva ALL; de Araújo TPG; de Albuquerque Ferreira SC; Leite AB; da Silva JKS; Albuquerque LWN; de Lima ARV; Barros HCS; Silva LR; da Silva-Júnior EF; de Araújo-Júnior JX; Neto VM; de Queiroz AC; Alexandre-Moreira MS
    Curr Protein Pept Sci; 2024; 25(1):12-26. PubMed ID: 37653631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition.
    Firat E; Niedermann G
    Oncotarget; 2016 Aug; 7(34):54883-54896. PubMed ID: 27448972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A practical review of prognostic correlations of molecular biomarkers in glioblastoma.
    Karsy M; Neil JA; Guan J; Mahan MA; Colman H; Jensen RL
    Neurosurg Focus; 2015 Mar; 38(3):E4. PubMed ID: 25727226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.
    Johansson P; Krona C; Kundu S; Doroszko M; Baskaran S; Schmidt L; Vinel C; Almstedt E; Elgendy R; Elfineh L; Gallant C; Lundsten S; Ferrer Gago FJ; Hakkarainen A; Sipilä P; Häggblad M; Martens U; Lundgren B; Frigault MM; Lane DP; Swartling FJ; Uhrbom L; Nestor M; Marino S; Nelander S
    Cell Rep; 2020 Jul; 32(2):107897. PubMed ID: 32668248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High frequency of temperature-sensitive mutants of p53 in glioblastoma.
    Smardova J; Liskova K; Ravcukova B; Kubiczkova L; Sevcikova S; Michalek J; Svitakova M; Vybihal V; Kren L; Smarda J
    Pathol Oncol Res; 2013 Jul; 19(3):421-8. PubMed ID: 23536279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.
    Krakstad C; Chekenya M
    Mol Cancer; 2010 Jun; 9():135. PubMed ID: 20515495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toosendanin Exerts an Anti-Cancer Effect in Glioblastoma by Inducing Estrogen Receptor β- and p53-Mediated Apoptosis.
    Cao L; Qu D; Wang H; Zhang S; Jia C; Shi Z; Wang Z; Zhang J; Ma J
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New therapeutic approaches in glioblastomas].
    Carpentier AF
    Bull Cancer; 2005 Apr; 92(4):355-9. PubMed ID: 15888392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor: a re-emerging target in glioblastoma.
    Hegi ME; Rajakannu P; Weller M
    Curr Opin Neurol; 2012 Dec; 25(6):774-9. PubMed ID: 23007009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.